01—Abstract
Summary
Summary of the 10-K filed February 10, 2021. Cited figures are marked; the original filing is the authoritative source.
Intuitive Surgical, Inc. (ISRG) reported a challenging year in 2020, impacted significantly by the COVID-19 pandemic which led to a 3% decrease in total revenue to $4.4 billiona.
Despite the revenue dip, the company demonstrated resilience, with procedure volumes seeing a modest 1%b increase to approximately 1.24 million, driven by growth in U.S. general surgery and global urology. The company's installed base of da Vinci Surgical Systems grew by 7% to 5,989 units, indicating continued strategic expansion despite short-term pandemic-related headwinds. Looking ahead, Intuitive Surgical is focused on innovation and expanding its product portfolio, as evidenced by investments in new technologies like the Ion endoluminal system and the da Vinci SP Surgical System.
The company also introduced an "Extended Use Program" for instruments to lower customer costs and is managing its operations and workforce to navigate the ongoing uncertainties. With a strong cash position of $6.87 billionc as of December 31, 2020, the company is well-positioned to manage through the current environment and invest in future growth opportunities, though the full impact of the pandemic on future procedure volumes and system placements remains uncertain.
02—Key points
Key Highlights
- Total revenue decreased by 3% to $4.4 billion in 2020, primarily due to a 12% decline in systems revenue, while instruments and accessories revenue saw a 2% increase, and service revenue remained flat.
- The company experienced a 16% decrease in da Vinci Surgical System shipments to 936 units in 2020, reflecting customer deferrals due to the COVID-19 pandemic.
- Despite system shipment declines, the da Vinci installed base grew by 7% to 5,989 systems as of December 31, 2020, demonstrating continued market penetration.
- Procedure volumes increased by 1% to 1.24 million for the year ended December 31, 2020, showing resilience despite significant pandemic disruptions.
- Gross profit margin decreased to 65.6% in 2020 from 69.4% in 2019, impacted by lower revenue, increased inventory costs, and pandemic-related operational factors.
- Operating income decreased by 24% to $1.05 billion, reflecting the revenue decline and increased R&D expenses.
- The company maintained a strong liquidity position with $6.87 billion in cash, cash equivalents, and investments as of December 31, 2020.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2020, Intuitive Surgical kept $0.24.
- Revenue$4.36B100.0%
- Cost of revenue−$1.50B34.4%
- Gross profit$2.86B65.6%
- Operating costs−$1.81B41.6%
- Operating income$1.05B24.1%
- Interest, other & tax$10.8M0.2%
- Net income$1.06B24.3%
Where FY2020 revenue went
$4.36B- Cost of revenue: $1.50B, 34% of revenue
- SG&A: $1.22B, 28% of revenue
- Operating income: $1.05B, 24% of revenue
- R&D: $595.1M, 14% of revenue
Kept 24% as operating incomeR&D $595.1M · 14%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 10, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $4.36B$4.48B | −2.7% |
| Cost of Revenue | $1.50B$1.37B | +9.4% |
| Gross Profit | $2.86B$3.11B | −8.0% |
| R&D Expenses | $595.10M$557.30M | +6.8% |
| SG&A Expenses | $1.22B$1.18B | +3.2% |
| Operating Expenses | $1.81B$1.74B | +4.4% |
| Operating Income | $1.05B$1.37B | −23.6% |
| Net Income | $1.06B$1.38B | −23.1% |
| EPS (Basic) | $3.02$3.98 | −24.1% |
| EPS (Diluted) | $2.94$3.85 | −23.6% |
| Shares Outstanding (Basic) | 351.10M346.20M | +1.4% |
| Shares Outstanding (Diluted) | 361.00M358.40M | +0.7% |
05—Questions
Frequently Asked Questions
How did the COVID-19 pandemic affect Intuitive Surgical's financial performance in 2020?
The COVID-19 pandemic significantly impacted Intuitive Surgical's financial performance in 2020. Total revenue decreased by 3% to $4.4 billion, primarily due to a 12% decline in systems revenue caused by customer deferrals of system purchases and leases. Procedure volumes, however, showed resilience with a 1% increase, but the overall impact of the pandemic led to a 24% decrease in operating income.
What is the outlook for system shipments and procedure volumes in the near term?
The company anticipates lower year-over-year system placements for the first quarter of 2021 due to ongoing pandemic impacts and hospitals prioritizing the use of existing capacity before purchasing new systems. While procedure volumes have shown resilience, the company cannot reliably estimate the extent to which the pandemic will impact future procedure volumes due to uncertainties surrounding infection rates, healthcare resource diversion, and economic conditions.
What are the company's key growth drivers and strategic priorities?
Intuitive Surgical's growth is driven by the increasing adoption of minimally invasive care through its da Vinci Surgical Systems and expansion into new areas like diagnostics with the Ion endoluminal system. Key strategic priorities include investing in innovation, expanding the product portfolio (e.g., da Vinci SP Surgical System), enhancing customer training and support, and optimizing manufacturing and supply chain capabilities. The company focuses on delivering value to patients, surgeons, and hospitals by improving surgical outcomes, enhancing the patient and care team experience, and lowering the total cost to treat.
How does the company manage its financial resources and liquidity?
Intuitive Surgical maintains a strong liquidity position, with $6.87 billion in cash, cash equivalents, and investments as of December 31, 2020. The company's primary source of liquidity is cash generated from operations. It also has an active stock repurchase program and invests in its business through capital expenditures and research and development, aiming to fund future growth through its operational cash flow.
06—Continue